secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-110344
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q3 2025 revenue $17.6M (+21% YoY); Emrosi sales $4.9M, prescriptions up 146%
--------------------------------------------------------------------------------

- Q3 2025 net revenues $17.6M, up 21% YoY from $14.6M; driven by Emrosi launch.
- Emrosi net sales $4.9M; prescriptions increased 146% sequentially vs Q2 2025.
- Net loss narrowed to $2.3M ($0.09/sh) from $2.4M ($0.12/sh) in Q3 2024.
- Adjusted EBITDA improved to positive $1.7M vs $0.3M in prior-year quarter.
- Gross margin 67.4% vs 69.4% in Q3 2024 (prior year benefited from one-time adjustments).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925110344/0001104659-25-110344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465925110344/tm2530914d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer